Footwear maker Pou Chen Corp (寶成工業) yesterday said that it has suspended production at its plant in Myanmar amid clashes between police and protesters following a military coup on Feb. 1, in which the military deposed civilian leader Aung San Suu Kyi.
Pou Chen provides original design manufacturing services to international brands, such as Nike Inc, Adidas AG, Asics Corp, New Balance Athletic Shoe Inc, Timberland Co and Salomon SAS.
The company said that the decision to stop production was made out of safety considerations.
Photo: EPA-EFE/STR
The suspension is not expected to have an adverse effect on Pou Chen’s overall operations, as the Burmese plant accounts for a fraction of its total production, the company said.
Its factories in Bangladesh, Cambodia and Myanmar account for about 4 percent of the firm’s total production, Pou Chen said, adding that the closure of the Burmese manufacturing facility would not cause any delays in shipments to customers.
If greater capacity is needed to meet demand, production would be increased at its plants in Indonesia and Vietnam to fill the void left by the Burmese plant, the company said.
Pou Chen’s business has been affected by the COVID-19 pandemic, with revenue from its shoe contracting business falling 24.6 percent last year from a year earlier.
Tsang Yi Co (昌億), another Taiwanese footwear maker that supplies shoes to Adidas, has also halted its production in Myanmar amid the violence there, the Ministry of Economic Affairs’ Invest Taiwan office said.
Pou Chen and Tsang Yi suspended their Burmese operations to protect their employees, and it is unclear when production would resume given the turmoil in the country, the office said.
UNCONVINCING: The US Congress questioned whether the company’s Chinese owners pose a national security risk and how the app might influence young users TikTok chief executive officer Shou Chew (周受資), confronted with an unforgiving, distrustful US Congress, tried to give answers in his testimony on Thursday that avoided offending either the US government or China. However, his evasiveness left Congress unsatisfied, with representatives hungrier than ever to punish TikTok for ties to its parent company ByteDance Ltd (字節跳動), based in Beijing. He did not bring his company any closer to a resolution. Politically, TikTok is in a tougher spot. Its executives had been discussing divesting from ByteDance to resolve US national security concerns, people familiar with the matter told Bloomberg. However, China this week said
The Investment Commission yesterday approved a Taiwan Semiconductor Manufacturing Co (TSMC, 台積電) application to invest an additional US$3.5 billion in its Arizona subsidiary to manufactured advanced chips. The world’s largest contract chipmaker’s board of directors last month approved the funding project after TSMC started moving manufacturing equipment into the fab in December last year in preparation for the production of 4-nanometer chips next year. TSMC said it has also commenced the second phase of facility construction in Arizona. The second fab is to produce semiconductors using 3-nanometer technology in 2026. Altogether, TSMC plans to spend US$40 billion on the Arizona fabs, doubling its
Microsoft Corp has threatened to cut off access to its Internet search data, which it licenses to rival search engines, if they do not stop using it as the basis for their own artificial intelligence (AI) chat products, people familiar with the dispute have said. The software maker licenses the data in its Bing search index — a map of the Internet that can be quickly scanned in real time — to other companies that offer Web search, such as Apollo Global Management Inc’s Yahoo and DuckDuckGo. Last month, Microsoft integrated a cousin of ChatGPT, OpenAI’s AI-powered chat technology, into Bing. Rivals
Sanofi SA’s drug Dupixent succeeded in a late-stage trial for chronic obstructive pulmonary disease (COPD), raising the odds that the blockbuster would be the first biologic medicine cleared to treat the lung disorder. Dupixent, which is already prescribed for asthma and some skin conditions, showed a 30 percent reduction in the rate at which patients’ COPD worsened compared with those who received a placebo during the stage-three Boreas trial, the company said in a statement yesterday. The positive data could herald a new era of cutting-edge treatments for the life-threatening respiratory affliction and provide another major boost in demand for the French
RSS